Nephron announces launch of OTC asthma inhalation product

Florida-based Nephron Pharmaceuticals has announced that it is launching an over-the-counter racepinephrine inhalation solution delivered by a device called the EZ Breathe Atomizer. The product will be marketed as Asthmanefrin and is being promoted as a substitute for the banned CFC Primatene Mist inhaler.

According to the company, the product will be available at Walmart and other retail stores beginning the first week in September. An Asthmanefrin starter kit will include the device and 10 vials of inhalation solution; a refill kit will include 30 vials.

Nephron CEO Lou Kennedy commented, “Until now, there has been no alternative to fill the void left by Primatene Mist CFC inhaler. As an industry leader in respiratory medications, introducing Asthmanefrin into the retail market is a natural choice for Nephron. We are proud to bring this quality, low-cost, OTC medication to the market. The use of Asthmanefrin, along with the pocket sized EZ Breathe Atomizer, will give bronchial asthma sufferers an excellent alternative treatment to Primatene Mist, at an affordable price.”

Read the Nephron press release.

Share

published on

May 10-May 14RDD 2026, Phoenix, AZ, USA

May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA

May 17-May 20: ATS International Conference 2026, Orlando, FL, USA

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan